( 3 minutes read)
· In an important development, Developers of the Russian COVID-19 vaccine –Sputnik V- has signed a deal with a leading Egyptian pharmaceutical company to manufacture more than 40 million doses annually in Cairo
· The vaccine to be manufactured in Egypt, is meant for global supply chain and the production facilities are being set up in Minapharm’s biotech facility in Cairo
· The Russian vaccine has demonstrated the efficacy of 97.6% and been approved by drug authorities in 61 countries so far
In an important development, Developers of the Russian COVID-19 vaccine –Sputnik V- has signed a deal with a leading Egyptian pharmaceutical company to manufacture more than 40 million doses annually in Cairo. This was revealed in a statement issued by the Russian Direct Investment Fund, along with Egypt’s Minapharm and its Berlin-based subsidiary. The statement said that the technology transfer would begin immediately to make available the vaccine by the third quarter of 2021.
The vaccine to be manufactured in Egypt, is meant for global supply chain and the production facilities are being set up in Minapharm’s biotech facility in Cairo. It is expected that Egypt might be used by the Sputnik –V manufacturers for exporting to other countries. The developers of the vaccine asserted that it is highly efficient and trusted by regulators around the world. They feel that Sputnik can make a huge contribution in the fight against the pandemic.
According to sources, the Russian vaccine has demonstrated the efficacy of 97.6% and been approved by drug authorities in 61
countries so far. Russia has been marketing Sputnik V abroad, despite the comparatively slow rollout at home and limited production capacities. It is now proposing to set up production centers in other countries including India.
